Skip to content

Mirum Pharmaceuticals, Inc. MIRM Available-for-Sale Debt Securities - Fair Value by Maturity

Available-for-Sale Debt Securities - Fair Value by Maturity at other companies

GBC
Glacier BancorpGBCI
$529.97M-39.0%
GBC
Glacier BancorpGBCI
$3.29B-9.4%
GBC
Glacier BancorpGBCI
$308.08M-41.3%
Kulicke & Soffa Industries logo
Kulicke & Soffa IndustriesKLIC
$0
Valley National Bank logo
Valley National BankVLY
$3.52B+16.1%
Ally Financial logo
Ally FinancialALLY
$4.87B+38.8%

Other financials

Income statement

See full
Revenue$159.9M+43.3%
Operating income-$789.5M-5,100%
Net income-$790.2M-5,284%
EPS (diluted)-$13.43-4,377%

Balance sheet

See full
Cash & equivalents$261.5M+43.5%
Total debt$13.5M+56.4%
Total equity$242.5M+4.0%
Total assets$890.9M+29.1%

Cash flow

See full
Operating cash flow-$228.8M-11,566%
CapEx$664.0K+1,520%
Free cash flow-$229.4M-11,360%

Valuation

See full
Market cap$6.53B+152%
Enterprise value$6.28B+162%
P/S11.5×+4.6×

Profitability

See full
Operating margin-139.8%-168pp
Net margin-140.2%-169pp
FCF margin-30.3%

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.1×-1.1×

Where this comes from

Reported directly by Mirum Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate.

The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mirum Pharmaceuticals, Inc.'s available-for-sale debt securities - fair value by maturity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mirum Pharmaceuticals, Inc.'s available-for-sale debt securities - fair value by maturity?
Mirum Pharmaceuticals, Inc. (MIRM) reported available-for-sale debt securities - fair value by maturity of $95.71M in Q1 2026.
How has Mirum Pharmaceuticals, Inc.'s available-for-sale debt securities - fair value by maturity changed year-over-year?
Mirum Pharmaceuticals, Inc.'s available-for-sale debt securities - fair value by maturity increased by 10.3% year-over-year, from $86.76M to $95.71M.